Cagrilintide + Semaglutide
A fixed 1:1 combination designed to produce superior, sustained weight loss (and, in type-2 diabetics, superior HbA1c reduction) versus either drug alone, by pairing two mechanistically distinct satiety pathways in one lockstep weekly regimen — this is Novo Nordisk's own designed and trial-tested purpose for the pairing, not a community-improvised stack.
Semaglutide (a GLP-1 drug) and cagrilintide (an amylin drug) each quiet hunger through a <b>different, barely-overlapping</b> brain pathway.
